Business Context and Reporting Period
Company: Regentis Biomaterials Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2025
Date of Filing: December 18, 2025
Principal Executive Offices: 60 Medinat Hayehudim Street, 4676652, Israel
This filing incorporates by reference a press release announcing that Regentis Biomaterials has been granted a new U.S. patent for its off-the-shelf regenerative cartilage repair product, GelrinC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event (patent grant) rather than a financial statement.
Material Changes
Intellectual Property Milestone: The company received a new U.S. patent for GelrinC, an off-the-shelf regenerative cartilage repair product. This represents a significant advancement in the company's intellectual property portfolio and product commercialization potential.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the strategic importance of the patent grant for the GelrinC product line.
Outlook: No specific financial guidance or future revenue projections are included in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the specific scope and claims of the newly granted U.S. patent for GelrinC.
- Confirm the current regulatory status and commercialization timeline for GelrinC in the U.S. market.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains no financial figures.
- Assess the competitive landscape for off-the-shelf regenerative cartilage repair products.